2/6/2019 8:09:18 AM
Eiger BioPharma Says Patent Protection For Lonafarnib Boosted With Ritonavir For HDV Infection In Europe And Japan
2/4/2019 8:14:31 AM
Eiger Says An Oral Presentation Granted For Results Of Phase 2 PREVENT Study At ENDO 2019
12/19/2018 8:09:02 AM
Eiger Says Breakthrough Therapy Designation Granted By FDA For Lonafarnib
12/18/2018 8:22:17 AM
Eiger Announces PRIME Designation Granted By EMA For Lonafarnib For Hepatitis Delta Virus Infection
12/17/2018 8:18:59 AM
Eiger Reports Breakthrough Therapy Designation Granted By FDA For Lonafarnib For Treatment Of HDV Infection
12/3/2018 4:08:07 PM
Eiger BioPharmaceuticals Appoints Sri Ryali As CFO
12/3/2018 8:12:36 AM
Eiger Reports FDA Acceptance Of IND Application For Lonafarnib For Treatment Of Progeria And Progeroid Laminopathies
11/9/2018 8:07:01 AM
Eiger BioPharmaceuticals Q3 Net Loss $17.1 Mln Or $1.20/Shr Vs Net Loss $9.2 Mln Or $1.10/Shr Last Year
10/23/2018 9:16:28 AM
Eiger Prices Public Offering Of 4.2 Mln Shares At $10.35/Shr
10/22/2018 4:12:39 PM
Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
10/22/2018 8:14:23 AM
Eiger BioPharma Gets FDA Rare Pediatric Disease Designation For Lonafarnib
9/24/2018 8:10:18 AM
Eiger Announces FDA Guidance On HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
8/13/2018 8:07:13 AM
Eiger BioPharma Announces Completion Of Enrollment In Phase 2 PREVENT Study Of Avexitide
8/13/2018 7:27:30 AM
Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) FY19 Estimate To -2.60 From -2.78
8/13/2018 7:27:13 AM
Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q4 19 Estimate To -0.69 From -0.73
8/13/2018 7:26:51 AM
Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) Q3 19 Estimate To -0.66 From -0.71
8/13/2018 7:26:33 AM
Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q2 19 Estimate To -0.64 From -0.68
8/13/2018 7:26:22 AM
Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) Q1 19 Estimate To -0.61 From -0.66